WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of ...

NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...

A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...

NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...

Do vitamin K antagonists affect COPD outcomes? New cohort data explore exacerbation and mortality risk compared with DOACs.

Milan, Italy: For the first time, researchers have shown it is possible to repair damaged lung tissue in patients with chronic obstructive pulmonary disease (COPD) using the patients’ own lung cells.

Both agents are long-acting muscarinic antagonists. The primary endpoint of the study was the change from baseline in trough FEV 1 at day 85. Findings showed no statistically significant difference ...

The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...